Plasma secretory phospholipase A2-IIa as a potential biomarker for lung cancer in patients with solitary pulmonary nodules

Table 3 High level of plasma sPLA2-IIa predicts lung cancer

Plasma sPLA2-IIa	< 2.4 ng/ml	> 2.4 ng/ml	Total case#	%Senstivity	%Specificity
Table 3a: Determination of plasma sPLA2-IIa to predict lung cancer by ROC analysis.
BNLCC lung cancer vs. benign SPN
Benign SPN	24	5	29		86
Lung cancer	50	46	96	48
Stage 1 lung cancer	24	20	44	45
Stage 2 lung cancer	6	12	18	67
GELCC lung cancer vs. benign SPN
Lung cancer	16	28	44	64
Table 3b: Combined sPLA2-IIa, CEA, and Cyfra21.1 blood tests increase the sentisitivity to predict lung cancer.
sPLA2-IIa	< 2.4 ng/ml	> 2.4 ng/ml
CEA	< 6.0 ng/ml	> 6.0 ng/ml	Total case#	%Senstivity	%Specificity
Cyfra21.1	< 3.3 ng/ml	> 3.3 ng/ml
BNLCC lung cancer vs. benign SPN
Benign SPN	22	7	29		76
Lung cancer	36	60	96	63
Stage 1 lung cancer	18	26	44	59
Stage 2 lung cancer	5	13	18	72
CEA	< 6.0 ng/ml	> 6.0 ng/ml	Total case#	%Senstivity	%Specificity
BNLCC lung cancer vs. benign SPN
Benign SPN	28	1	29		97
Lung cancer	77	19	96	20
Cyfra21.1	< 3.3 ng/ml	> 3.3 ng/ml	Total case#	%Senstivity	%Specificity
BNLCC lung cancer vs. benign SPN
Benign SPN	27	2	29		93
Lung cancer	83	13	96	14

ISSN: 1471-2407